Reboxetine, a selective noradrenaline reuptake inhibitor, is non-sedative and does not impair psychomotor performance in healthy subjects
- 1 August 1998
- journal article
- research article
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 13 (6) , 425-433
- https://doi.org/10.1002/(sici)1099-1077(199808)13:6<425::aid-hup17>3.0.co;2-r
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodesEuropean Neuropsychopharmacology, 1997
- Noradrenaline in basic models of depressionEuropean Neuropsychopharmacology, 1997
- The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performanceBritish Journal of Clinical Pharmacology, 1996
- Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein bindingBiopharmaceutics & Drug Disposition, 1995
- Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United StatesArchives of General Psychiatry, 1994
- Side-effects of AntidepressantsThe British Journal of Psychiatry, 1993
- The Toxicity of AntidepressantsThe British Journal of Psychiatry, 1989
- Critical Flicker Fusion Frequency (CFF): The Effects of Psychotropic CompoundsPharmacopsychiatry, 1982
- COMPARATIVE STUDY OF THE EFFECTS OF ORAL AND I.M. ATROPINE AND HYOSCINE IN VOLUNTEERSBritish Journal of Anaesthesia, 1978
- Der Pauli-TestPublished by Springer Nature ,1975